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Introduction
From 2009-2020, guidelines for vancomycin dosing were avail-
able through a joint effort from the American Society of 
Health-System Pharmacists (ASHP), the Infectious Diseases 
Society of America (IDSA), and the Society of Infectious 
Diseases Pharmacists (SIDP).1 Despite availability of these 
guidelines and over 50 years of clinical experience, much 
remains unknown regarding the optimal use of vancomycin in 
clinical practice.2 A 2013 survey of infectious diseases pharma-
cists revealed discordance between vancomycin practices and 
guideline recommendations, particularly regarding a reluctance 
to use loading doses in seriously ill patients, to use actual body 
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ABSTRACT
InTRoDuCTIon: Critically ill patients and their pharmacokinetics present complexities often not considered by consensus guidelines from 
the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases 
Pharmacists. Prior surveys have suggested discordance between certain guideline recommendations and reported infectious disease phar-
macist practice. Vancomycin dosing practices, including institutional considerations, have not previously been well described in the critically 
ill patient population.
oBjeCTIVeS: To evaluate critical care pharmacists’ self-reported vancomycin practices in comparison to the 2009 guideline recommenda-
tions and other best practices identified by the study investigators.
MeThoDS: An online survey developed by the Research and Scholarship Committee of the Clinical Pharmacy and Pharmacology (CPP) 
Section of the Society of Critical Care Medicine (SCCM) was sent to pharmacist members of the SCCM CPP Section practicing in adult inten-
sive care units in the spring of 2017. This survey queried pharmacists’ self-reported practices regarding vancomycin dosing and monitoring 
in critically ill adults.
ReSulTS: Three-hundred and sixty-four responses were received for an estimated response rate of 26%. Critical care pharmacists self-
reported largely following the 2009 vancomycin dosing and monitoring guidelines. The largest deviations in guideline recommendation com-
pliance involve consistent use of a loading dose, dosing weight in obese patients, and quality improvement efforts related to systematically 
monitoring vancomycin-associated nephrotoxicity. Variation exists regarding pharmacist protocols and other practices of vancomycin use in 
critically ill patients.
ConCluSIon: Among critical care pharmacists, reported vancomycin practices are largely consistent with the 2009 guideline recommen-
dations. Variations in vancomycin dosing and monitoring protocols are identified, and rationale for guideline non-adherence with loading 
doses elucidated.
KeywoRDS: Vancomycin, critical care, therapeutic drug monitoring, guideline, continuous infusion, dose, monitoring
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weight for dose calculation in obesity, and to systematically 
monitor for complications such as nephrotoxicity.3
The compliance of pharmacists and physicians with guideline 
recommendations for vancomycin dosing and monitoring is 
important from an overall antimicrobial stewardship perspective, 
but is of particular importance in the critical care setting for sev-
eral reasons. The complexities of the intensive care unit (ICU) 
patient population introduce additional challenges to a complex 
drug. The acuity of the patient population demands adequate 
pharmacokinetic-pharmacodynamic target attainment for seri-
ous, life-threatening infections while minimizing the risk of 
nephrotoxicity for patients already at risk of acute kidney injury 
and often simultaneously prescribed multiple other nephrotox-
ins. Critically ill patients’ clearance of vancomycin could vary, 
from significant decreases in acute kidney injury to clinically sig-
nificant increases in the setting of augmented renal clearance. 
Adjustments for other medical therapies, such as continuous 
renal replacement therapy (CRRT) and other dialysis modali-
ties, represent unique circumstances that may not be addressed 
by guidelines. Other “best practice” items related to vancomycin 
dosing in the critically ill are likely variable across ICU pharma-
cists due to unique aspects of this patient population.
If any discordant areas of practice deviate in a substantial way 
from guideline recommendations, understanding factors driving 
critical care pharmacists’ decisions to do so are important to eluci-
date and represent cornerstones of implementation science efforts. 
The purpose of this survey was to determine if this variability 
exists in an effort to potentially inform future guideline recom-
mendations and to reduce variability in evidence-based practices. 
We sought to build on a prior survey of vancomycin use3 in the 
following ways: (1) To perform a more recent survey of practice 
patterns given the continuously updated literature on vancomycin 
since 2013, (2) To study under which clinical scenarios ICU phar-
macists may not adhere to guideline recommendations and ascer-
tain why, (3) To characterize practice patterns regarding 
ICU-centric dosing challenges that may not be addressed in con-
sensus guidelines, and (4) To explore respondent characteristics 
associated with compliance to guideline recommendations or 
early adoption of certain vancomycin dosing practices.
Materials and methods
Survey design
A survey was developed by a pharmacist working group of the 
Society of Critical Care Medicine (SCCM) Clinical Pharmacy 
and Pharmacology (CPP) Research and Scholarship Committee 
in early 2017. This survey was approved by the University of 
Kentucky Institutional Review Board as an exempt study.
Survey questions were developed by the working group using 
the 2009 ASHP/IDSA/SIDP guidelines as a template.1 Once 
guideline recommendations were addressed in the survey, addi-
tional survey questions were created to capture areas of what the 
authors considered “best practice” or areas where substantial 
variability in practice was hypothesized to exist; for example, 
whether pharmacists were alerted to initiation or 
discontinuation of renal replacement therapies to adjust dosing 
accordingly. The survey was a 24-item questionnaire, with six 
general demographic questions, eight vancomycin-related 
demographic questions regarding the practice site, and 10 ques-
tions related to individual clinician’s vancomycin dosing prac-
tices (Appendix).
A modified Likert scale was used: rarely (<10% of the 
time); sometimes (10-50% of the time); often (51-90% of the 
time); and routinely (>90% of the time) was used for questions 
of which a frequency of a particular action was inquired (eg. 
how often a clinician would recommend an intervention). A 
pilot survey was performed by five non-critical care pharma-
cists to establish face and content validity of the survey instru-
ment. Six critical care pharmacists not involved on the study 
team took the survey to estimate time required for completion 
and provide any additional feedback or areas for clarification. 
Verbal and written feedback from all pilot tests were incorpo-
rated into the final survey by the research team. The survey 
required approximately 10-15 minutes for completion.
Cross-sectional survey
Invitations to complete the survey were sent over e-mail twice, 
two weeks apart during April of 2017. The survey was adminis-
tered through and data collected using REDCap electronic data 
capture tools hosted at the University of Kentucky.4 Invitations 
were sent out electronically via SCCM staff to all SCCM mem-
bers of the CPP section, which includes pharmacist and non-
pharmacist members. Pharmacist members of CPP practicing in 
adult critical care settings were specifically invited to take the 
survey and represent the target population of interest. Non-
pharmacist members, or pharmacists practicing in a pediatric 
critical care setting, were asked not to respond to the survey.
Statistical analysis
Data were analyzed with Stata (StataCorp. 2015. Stata 
Statistical Software: Release 14. College Station, TX: 
StataCorp LP). Categorical data from the survey are pre-
sented as proportions. Exploratory logistic regression analy-
ses were undertaken to evaluate factors associated with the 
following: selection of often or routinely (eg. >50% of the 
time) for loading doses for all six clinical scenarios examined, 
use of area-under-the-curve (AUC) as pharmacokinetic tar-
get parameter, and self-reported comfort with AUC calcula-
tions (ie. somewhat or extremely comfortable). Candidate 
predictor variables identified a priori by the study team 
thought to influence vancomycin dosing practices included: 
region, practitioner years of experience, hospital type, hospital 
size, and ICU type. Due to complete separation of variables in 
some of the regression models, a penalized maximum likeli-
hood regression model was used with the f irthlogit package in 
Stata.5-7 Output from regression models are presented as 
odds ratios (OR) with 95% confidence intervals (CI). Two-
sided P-value <.05 was considered statistically significant.
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Results
Survey response rate
The survey was delivered to 2,305 SCCM CPP members 
(includes pharmacists and non-pharmacists) via e-mail using the 
SCCM CPP section distribution list. Approximately 1,500 of 
these members are pharmacists within the CPP section per the 
SCCM demographic database. Based on internal demographic 
data from the section indicating that approximately 100 phar-
macists practiced in pediatric critical care, we estimate that 1,400 
of these pharmacists practiced in an adult ICU setting and would 
be eligible for the survey. We received 364 responses, for an esti-
mated response rate of 26%.
Respondent demographics
Respondent demographics are presented in Table 1. 
Approximately half (48%) of respondents were from urban 
academic medical centers. The two most frequent responses for 
institutional bed size were 250-499 beds and 500-750 beds. 
The large majority of respondents (>97%) were from the 
United States with relatively similar representation from all 
major geographic areas. A majority of pharmacists participat-
ing in the survey were clinical practitioners <5 years (33%) or 
5-10 years (29%) removed from their terminal training. These 
pharmacists most frequently practiced in a medical (30%) or 
mixed medical/surgical (32%) ICU. Over 90% of pharmacist 
respondents reported that a pharmacist rounded with the pri-
mary or intensivist team at least five days per week.
Vancomycin-related practices in respondent 
institutions
Practice site characteristics regarding vancomycin are presented 
in Table 2. The most common responses regarding what per-
centage of Staphylococcus aureus isolates were methicillin-resist-
ant Staphylococcus aureus (MRSA) were either 20-39% (23% of 
respondents) or 40-59% (34% of respondents). Vancomycin 
was routinely reported as empiric therapy in hospital-acquired 
infections by 67% of respondents. Fifty-five percent of respond-
ents estimated the average duration of vancomycin use prior to 
de-escalation when MRSA is not cultured as 48-72 hours. A 
large majority of respondents (85%) reported that their institu-
tion reports the vancomycin minimum inhibitory concentra-
tions for MRSA in the medical record.
Approximately one-third of respondents (31%) reported 
their institution had no formal pharmacy consult order (or 
pharmacy to dose protocol) to dose vancomycin. Another 
31% of respondents reported that pharmacists may deviate 
from the protocol as written, which they sometimes do (10-
50% of the time). The majority of pharmacists had a protocol 
or other mechanism in place to order vancomycin serum con-
centrations (83%), laboratory monitoring (eg. basic metabolic 
panel) (72%), or dose adjust according to vancomycin serum 
concentration or renal function (78%); 18% of respondents 
reported no formal mechanism for placing these orders, 
requiring they be placed under a provider’s name pursuant to 
a verbal or written order.
Twenty percent of respondents reported a protocol for van-
comycin dosing in the setting of CRRT with a mechanism to 
alert the pharmacist that CRRT is being initiated or discontin-
ued; another 30% have a protocol with no mechanism to alert 
the pharmacist of CRRT initiation or discontinuation. Most 
Table 1. Respondent demographics.
NUMbER (%)
Practice Region
 Midwestern United States 111/364 (30.5)
 Southern United States 109/364 (30.0)
 Western United States 74/364 (20.3)
 Northeastern United States 60/364 (16.5)
 Outside of United States 10/364 (2.7)
Institutional Setting
 Academic medical center/urban 174/364 (47.8)
 Community hospital/teaching/urban 89/364 (24.5)
 Community hospital/non-teaching/urban 44/364 (12.1)
  Other (including government and rural 
hospitals)
57/364 (15.6)
Institution Size
 <250 beds 55/364 (15.1)
 250-499 beds 119/364 (32.7)
 500-750 beds 99/364 (27.2)
 >750 beds 91/364 (25.0)
Current level of Training
  Current PGY2 specialty pharmacy resident 
(any specialty)
35/364 (9.6)
  Practitioner less than 5 years out from 
terminal training
121/364 (33.2)
  Practitioner 5-10 years out from terminal 
training
104/364 (28.6)
  Practitioner more than 10 years out from 
terminal training
99/364 (27.2)
 Other 5/364 (1.4)
Primary location or Service
 Cardiothoracic ICU 20/364 (5.5)
 Emergency Department 20/364 (5.5)
 Medical ICU 109/364 (29.9)
 Mixed Medical/Surgical ICU 115/364 (31.6)
 Surgical/Trauma ICU 49/364 (13.5)
 Other 51/364 (14.0)
Pharmacists Physically Round with the Primary or Intensivist 
Team ⩾5 days/week
 Yes 332/364 (91.2)
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Table 2. Practice site characteristics and vancomycin-related demographics.
NUMbER (%)
Institutional Protocol Description and Pharmacist Adherence
 Pharmacists must adhere to the protocol as written and may not deviate 8/364 (2.2)
 Pharmacists may deviate from the protocol as written, but I rarelya do 36/364 (9.9)
 Pharmacists may deviate from the protocol as written, which I sometimesb do 111/364 (30.5)
 Pharmacists may deviate from the protocol as written, which I oftenc do 63/364 (17.3)
 Pharmacists may deviate from the protocol as written, and I routinelyd do 34/364 (9.3)
 No formal protocol exists in my primary practice 112/364 (30.8)
Pharmacist Authorized to order
 Vancomycin levels 303/364 (83.2)
 Laboratory tests for monitoring (eg. basic metabolic panel) 262/364 (72.0)
 Dose adjustments based on vancomycin levels or renal function changes 283/364 (77.8)
Institutional Protocol for Vancomycin Dosing in Continuous Renal Replacement Therapy (CRRT)
 Yes; but there is no mechanism to alert the pharmacist that CRRT is being initiated or discontinued 109/364 (29.9)
 Yes; and there is a mechanism to alert the pharmacist that CRRT is being initiated or discontinued 71/364 (19.5)
 No; and there is no mechanism to alert the pharmacist that CRRT is being initiated or discontinued 93/364 (25.6)
 No; but there is a mechanism to alert the pharmacist that CRRT is being initiated or discontinued 51/364 (14.0)
 Primary practice ICU does not utilize CRRT 40/364 (11.0)
Institutional Vancomycin Monitoring and Quality Assurance Programs
 Quality assurance for percentage of vancomycin dosing regimens within goal target parameters 96/364 (26.4)
 Real-time clinical decision support to notify pharmacists of acute changes in serum creatinine or urine output 90/364 (24.7)
 Standardized definition of vancomycin-associated nephrotoxicity 27/364 (7.4)
 None of these 159 (43.7)
estimated Methicillin Resistant Staphylococcus aureus Isolates
 20-39% 84/364 (23.1)
 40-59% 122/364 (33.5)
 60-80% 25/364 (6.9)
 Other 32/364 (8.8)
 Unknown/No specific antibiogram 101/364 (27.7)
estimated Frequency of empiric Vancomycin Therapy for Suspected hospital-Acquired Infections
 Rarelya 6/364 (1.6)
 Sometimesb 16/364 (4.4)
 Oftenc 99/364 (27.2)
 Routinelyd 243/364 (66.8)
estimated Average Duration of Vancomycin use Prior to De-escalation when MRSA is not Cultured
 <2 days (<48 hours) 16/364 (4.4)
 2-3 days (48-72 hours) 201/364 (55.2)
 3-4 days (72-96 hours) 109/364 (30.0)
 >4 days (>96 hours) 38/364 (10.4)
a<10% of the time; b10-50% of the time; c51-90% of the time; d>90% of the time.
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respondents (60%) did not use sustained low efficiency dialysis 
(SLED) at their practice site.
When asked which vancomycin monitoring and quality assur-
ance programs were offered at their institutions, respondents 
indicated low rates of participation with regard to quality assur-
ance for percentage of vancomycin dosing within a goal parame-
ter (26%), clinical decision support to identify acute changes in 
serum creatinine or urine output (25%), and standardized defini-
tion of vancomycin-associated nephrotoxicity (7%).
Respondent vancomycin dosing practices
Complete results are displayed in Table 3. With respect to sce-
nario-based questions regarding use of vancomycin loading doses, 
responses were mixed across scenarios. The percentage of phar-
macists reporting either routinely or often (51-90% of the time) 
using a loading dose for the surveyed conditions were as follows: 
meningitis/CNS infection (84%), septic shock (79%), infective 
endocarditis (75%), pneumonia in a mechanically ventilated 
patient (69%), sepsis without shock (61%), and pneumonia in a 
non-mechanically ventilated patient (54%). When respondents 
were asked why they did not administer a loading dose at times 
for a critically ill patient, the most common response was that 
their assessment of the patient did not meet the definition of 
severely ill (40%), followed by lack of clinical outcome data sup-
porting the loading dose strategy (23%) and nephrotoxicity con-
cerns (20%). Written comments by survey respondents suggested 
other possible reasons, including physician concerns for nephro-
toxicity and logistics of having to compound the loading dose in 
the pharmacy versus using doses readily available in the patient 
care area from automated dispensing cabinets.
Over 90% of respondents reported using actual body weight 
for loading doses and maintenance doses in normal or under-
weight patients. For overweight or obese patients, 56% of respond-
ents reported using actual body weight (41% used adjusted body 
weight) for a loading dose and 45% of respondents reported using 
actual body weight (51% used adjusted body weight) for mainte-
nance dosing. The most commonly reported dose cap for a load-
ing dose was 2,000 mg (45%) followed by 2,500 mg (28%), while 
2,000 mg was the most commonly reported dose cap for mainte-
nance dosing with the majority of respondents (75%).
The majority of respondents reported rarely assessing post-
loading dose concentrations, two level kinetics following the 
first dose, and peak levels. The vast majority (87%) of respond-
ents reported using trough values while 13% reported using 
trough and AUC. When using trough values, 24% of respond-
ents report that doses are held routinely pending evaluation of 
the level, while 64% report doses are held pending evaluation 
only in the setting of suspected acute kidney injury.
Pharmacists most commonly (92%) reported administering 
vancomycin via intermittent infusion with the majority of phar-
macists rarely using continuous infusion. Pharmacist perception 
of their comfort level with AUC calculations was variable with 
intermittent infusion. The majority of respondents (62%) report 
being not at all comfortable with AUC calculations for continu-
ous infusions.
In exploratory regression models, respondents from larger 
hospitals were overall less likely than smaller hospitals to report 
consistently using loading doses often or routinely in all six sce-
narios presented: 250-499 beds (OR 0.4, 95% CI 0.2-0.9), 500-
750 beds (OR 0.4, 95% CI 0.2-0.9), and >750 beds (OR 0.4, 
95% CI 0.2-0.8) [reference hospitals with <250 beds]. Europe 
(OR 22.8, 95% CI 2.3-228.7) and Western US regions (OR 3.6, 
95% CI 1.5-8.6) were more likely to report using AUC as a target 
pharmacokinetic parameter for vancomycin use. No predictors 
were identified for reported comfort with AUC calculations.
Discussion
Compliance with clinical practice guidelines is influenced by 
many factors, notably the quality of the guidelines themselves, 
users of the guidelines, and implementation context.8 Critical 
care pharmacists were overall compliant with many of the 2009 
guideline recommendations assessed except for a few particular 
areas. Specifically, we observed inconsistent use of a loading dose, 
dosing weight in obese patients, and quality improvement efforts 
related to systematically monitoring vancomycin-associated 
nephrotoxicity.
A survey of infectious disease pharmacist self-reported 
adherence to the 2009 guidelines was previously published in 
2013.3 Key variations in infectious disease pharmacist 
reported practices from 2009 guideline recommendations 
involved the recommendations around loading doses in seri-
ously ill patients (only 42% reported always), use of actual 
body weight to dose obese patients (40% reported sometimes; 
52% reported always), and systematically monitoring nephro-
toxicity with a standard definition to routinely identify and 
report vancomycin-associated nephrotoxicity (34% reported 
never; 35% reported sometimes).3 The authors of this study 
noted it imperative to discern reasons for noncompliance to 
the loading dose recommendation, particularly in severely ill 
patients who may benefit and have altered pharmacokinetics.3 
Our survey builds on prior work with a larger and more 
diverse study sample and is unique by focusing on adult criti-
cal care pharmacists, includes survey items regarding sources 
of practice variation related to vancomycin in critically ill 
patients, and investigates reasons for pharmacists not adher-
ing to certain 2009 guideline recommendations.
Our survey also identified variation in compliance with 
loading dose recommendations; however, some pharmacists 
report practicing differently in specific scenarios. In particular, 
their assessment of severity of illness appears to be a large fac-
tor in administering a loading dose. Although some respond-
ents may consider an ICU patient “severely ill” as the 2009 
guidelines term it, this classification can be subjective.1 Lack 
of clinical outcomes behind the 2009 recommendation for 
loading doses (IIIB recommendation) and concerns of 
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Table 3. Vancomycin dosing and monitoring strategies.
FREQUENCY OF LOADING DOSE RECOMMENDATION bY INDICATION
 RARELYa SOMETIMESb OFTENc ROUTINELYd
 Infective endocarditis 52/364 (14.3) 40/364 (11.0) 70/364 (19.2) 202/364 (55.5)
 Meningitis/CnS infection 33/364 (9.1) 27/364 (7.4) 54/364 (14.8) 250/364 (68.7)
 Pneumonia in a MV patient 51/363 (14.1) 60/363 (16.5) 75/363 (20.7) 177/363 (48.8)
 Pneumonia in a non-MV patient 94/363 (25.9) 74/363 (20.4) 71/363 (19.6) 124/363 (34.2)
 Sepsis with shock 40/364 (11.0) 38/364 (10.4) 68/364 (18.7) 218/364 (59.9)
 Sepsis without shock 67/363 (18.5) 74/363 (20.4) 82/363 (22.6) 140/363 (38.6)
Pharmacist Reasoning when Choosing not to Administer a loading Dose
 lack of clinical outcome data supporting strategy 83/364 (22.8)
 nephrotoxicity concerns 73/364 (20.1)
 Time required to infuse 13/364 (3.6)
 The patient does not meet my definition of severely ill 146/364 (40.1)
 other 71/364 (19.5)
MOST COMMONLY USED WEIGHT FOR DOSING VANCOMYCIN
 ACTUAL bODY 
WEIGHT
IDEAL bODY 
WEIGHT
ADJUSTED bODY 
WEIGHT
 loading dose for normal/underweight patients 353/361 (97.8) 5/361 (1.4) 3/361 (0.8)
 loading dose for overweight/obese patients 201/361 (55.7) 12/361 (3.3) 148/361 (41.0)
 Maintenance dose for normal/underweight patients 341/361 (94.5) 9/361 (2.5) 11/361 (3.1)
 Maintenance dose for overweight/obese patients 162/361 (44.9) 16/361 (4.4) 183/361 (50.7)
MOST COMMONLY USED DOSE CAP
 2000 MG PER DOSE 2500 MG PER 
DOSE
3000 MG PER DOSE >3000 MG PER 
DOSE
NO CAP/MAx 
DOSE
 loading dose 164/362 (45.3) 102/362 (28.2) 61/362 (16.9) 8/362 (2.2) 27/362 (7.5)
 Maintenance dose 273/362 (75.4) 43/362 (11.9) 10/362 (2.8) 2/362 (0.6) 34/362 (9.4)
USE OF THE FOLLOWING STRATEGIES TO ASSESS VANCOMYCIN ExPOSURE AND CALCULATE FURTHER DOSING
 RARELYa SOMETIMESb OFTENc ROUTINELYd
 Collect a post-loading dose level 322/361 (89.2) 29/361 (8.0) 3/361 (0.8) 7/361 (1.9)
 Two-level kinetics after first dose 277/361 (76.7) 63/361 (17.5) 14/361 (3.9) 7/361 (1.9)
 Collect peak levels 325/361 (90.0) 21/361 (5.8) 6/361 (1.7) 9/361 (2.5)
 Collect trough levels 9/362 (2.5) 18/362 (5.0) 32/362 (8.8) 303/362 (83.7)
Frequency of Doses held Pending level evaluation when Trough levels are Collected
 Doses are held routinely (>90% of the time) pending level evaluation 87/362 (24.0)
 Doses are held pending level evaluation only if kidney injury is suspected or known 233/362 (64.4)
 Doses are held rarely (<10% of the time), even if kidney injury is suspected or known 42/362 (11.6)
Target Pharmacokinetic Dosing and Monitoring Parameter
 Trough 314/363 (86.5)
 AuC 2/363 (0.6)
 Trough and AuC 47/363 (12.9)
 (Continued)
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FREQUENCY OF VANCOMYCIN DOSING VIA METHOD OF ADMINISTRATION
 RARELYa SOMETIMESb OFTENc ROUTINELYd
 Intermittent infusion 10/364 (2.8) 11/364 (3.0) 8/364 (2.2) 335/364 (92.0)
 Continuous infusion 342/363 (94.2) 16/363 (4.4) 3/363 (0.8) 2/363 (0.6)
COMFORT LEVEL ASSESSING VANCOMYCIN LEVELS TO CALCULATE AUC
 NOT AT ALL 
COMFORTAbLE
SOMEWHAT 
UNCOMFORTAbLE
SOMEWHAT 
COMFORTAbLE
ExTREMELY 
COMFORTAbLE
 Intermittent infusion 134/363 (36.9) 54/363 (14.9) 100/363 (27.6) 75/363 (20.7)
 Continuous infusion 223/362 (61.6) 59/362 (16.3) 49/362 (13.5) 31/362 (8.6)
a<10% of the time; b10-50% of the time; c51-90% of the time; d>90% of the time; AUC, area-under-the-curve; CNS, central nervous system; MV, mechanically ventilated.
Table 3. (Continued)
nephrotoxicity in an already at-risk patient population are also 
commonly reported reasons for selectively administering load-
ing doses.1 Concerns of nephrotoxicity with loading doses by 
physician colleagues were also noted in the written responses 
from pharmacist respondents in this survey and identified as 
potential barriers to routinely using loading doses.
There were similar discrepancies between using actual body 
weight for dosing in obese patients between the two surveys, 
with a number of pharmacists in the current survey reporting use 
of an adjusted body weight.3 The pharmacokinetics of vancomy-
cin are known to be an area of controversy in obese patients.9 
Due to the hydrophilicity of vancomycin and the increase in adi-
pose tissue associated with obesity, its volume of distribution is 
somewhat increased in obese patients. In addition, various dos-
ing weights, including ideal body weight, total body weight, and 
adjusted body weight, have been evaluated in estimating clear-
ance of vancomycin with conflicting results.10 Given the com-
plexity of critically ill, obese patients and a lack of strong evidence 
for how to optimally dose vancomycin in these patients, it is not 
surprising that our survey revealed such practice variation.
In both our survey and that of Davis et al.,3 there do seem to 
be opportunities related to standardized definitions of vancomy-
cin-associated nephrotoxicity and quality improvement programs 
to track and monitor this complication.3 The possibility exists 
that this is done within the context of antimicrobial stewardship 
programs and surveyed ICU pharmacists may not be aware, but 
this was reported as similarly low in the survey of infectious dis-
eases pharmacists.3 Additionally, an opportunity may exist for 
more institutions to implement CRRT alert triggers for pharma-
cists to increase or decrease doses, as appropriate.
The majority of critical care pharmacists surveyed rarely 
employed continuous infusion dosing of vancomycin. 
Interestingly, recent evidence suggests that continuous infusions 
may be less nephrotoxic than intermittent infusions, particularly 
in critically ill patients.11-13 Of paradoxical interest is that phar-
macists were reportedly far less comfortable with AUC calcula-
tions for continuous infusions than with intermittent infusions, 
given the AUC calculations for continuous infusion are much 
simpler than for intermittent dosing. The varying comfort level 
with AUC calculations in this survey demonstrates the impor-
tance of educational efforts that will be needed to employ 
AUC-guided dosing in ICU patients on a larger scale, as is rec-
ommended by the revised vancomycin consensus guidelines 
recently published in May of 2020.14
Our exploratory analysis found that respondents from 
larger hospitals were generally less likely to report consistent 
use of loading doses compared to respondents from hospitals 
with <250 beds. While the exact reasoning for this is 
unknown, it could be due to a relatively smaller number of 
respondents from hospitals with <250 beds (15.1% of 
respondents) or perhaps improved compliance with protocols 
and guideline recommendations in smaller hospitals from this 
survey. Additionally, our analysis suggests geographic varia-
tion in early adoption of AUC to guide vancomycin dosing, 
with greater adoption in Western United States and Europe 
at the time our survey was administered. Pharmacist educa-
tion is clearly required for AUC dosing and monitoring given 
the reported comfort rates. Although the pharmacokinetic 
assumptions are fewer and calculations easier with continu-
ous infusion, this may simply represent the unfamiliarity of 
critical care pharmacists surveyed with employing continuous 
infusions due to the low frequency of use identified.
Our study has important limitations to acknowledge. Only 
SCCM CPP members participated in the study; thus, reported 
behaviors from non-survey responders and non-SCCM CPP 
members may be different. This survey only inquired about self-
reported actions regarding vancomycin and may not reflect 
actual actions from clinicians in their practice. Multiple respond-
ents may have responded from the same institution, thus biasing 
some reported metrics. Our response rate of 26% limited the 
number of respondents that we were able to collect data from, 
however, our study is more than twice as large as the prior study 
of vancomycin dosing practices.3 Although Europe was identi-
fied as using AUC more than others in this survey, there were 
few respondents from Europe, which may only represent a few 
institutions and not be representative of European practice. 
Finally, our survey was disseminated in the spring of 2017, and 
we suspect additional centers have transitioned to AUC 
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monitoring at this time given a signal of increased safety in terms 
of kidney injury as well as anticipated (and actual) endorsement 
of AUC guided dosing in recently released revised consensus 
vancomycin guidelines.14-16 Although these revised guidelines 
have been published since our survey, aside from recommending 
a change from trough-based dosing to AUC and no longer 
directly recommending actual body weight in maintenance dos-
ing for obesity, many of the recommendations as they relate to 
our survey remain similar between the 2009 and 2020 guide-
lines.1,14 Table 4 compares relevant dosing considerations from 
our survey between the 2009 and 2020 guidelines.1,14 Our data 
may serve as a benchmark in evaluating uptake of consensus 
guideline recommendations, particularly against the backdrop of 
showing a relatively low “early-adopter” rate for AUC-guided 
dosing. In the context of newly revised consensus guidelines, we 
also show continued room for improvement with the guideline 
recommendation for loading doses, and demonstrate that a small 
percentage of surveyed pharmacists are employing continuous 
infusion. Finally, our survey also establishes the prevalence of 
important dosing concepts that may not be presented as formal 
guideline recommendations yet may reflect best practices in dos-
ing vancomycin in critically ill patients, including electronic 
alerts for CRRT initiation or discontinuation.
Conclusion
Critical care pharmacists’ reported practices regarding vancomy-
cin are largely consistent with the 2009 vancomycin guideline 
recommendations. Important areas of variation include use of 
loading doses, dosing weights in obese patients, and quality 
improvement efforts related to systematically monitoring vanco-
mycin-associated nephrotoxicity. Further study in these particu-
lar areas may allow more definitive guideline recommendations 
to help optimize vancomycin use in the critically ill.
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